← Back to patent-cliff list
Toviblideg
Tier C — Watch / tradeToviblideg
Bristol Myers Squibb
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BCL6
Indications (approved)：Non-Hodgkin lymphoma
Regional status
US
Phase II
2023-12-29
EU
Phase II
2023-12-29
China
Phase II
2023-12-29
Japan
Phase II
2023-12-29
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Toviblideg?
Approved indications include: Non-Hodgkin lymphoma.
When does the Toviblideg patent expire?
No public expiry year is available for Toviblideg yet; this page updates once verified.
How do I get a quote for Toviblideg intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02